Agilon Health chief markets officer Shaker Benjamin sells $16,779 in stock

Published 18/03/2025, 23:44
Agilon Health chief markets officer Shaker Benjamin sells $16,779 in stock

In a recent transaction involving agilon health , inc. (NYSE:AGL), Shaker (TADAWUL:1214) Benjamin, the company’s Chief Markets Officer, reported the disposition of common stock valued at $16,779. The shares were withheld by the issuer to meet tax obligations related to the net settlement of performance-based restricted stock units (PSUs). The transaction, dated March 14, 2025, involved 4,143 shares at $4.05 per share. The stock, which has shown remarkable strength with a 12.21% gain in the past week, currently trades at $4.32. InvestingPro analysis indicates the stock is trading near its Fair Value, with additional insights available in the comprehensive Pro Research Report.

On the same day, Benjamin acquired 11,786 shares of common stock through the vesting of PSUs. These awards were granted on April 14, 2022, and vested based on agilon health’s performance metrics, achieving 87% of the predetermined goals over a three-year period. Following these transactions, Benjamin holds a total of 457,058 shares, including restricted stock units. The company, currently valued at $1.79B, has demonstrated strong momentum with a year-to-date return of 127.37%. InvestingPro subscribers can access 10+ additional expert insights about AGL’s financial health and market position.

In other recent news, Agilon Health reported a mixed financial performance for the fourth quarter of 2024, with revenue reaching $1.52 billion, surpassing forecasts, but earnings per share (EPS) missing expectations at -$0.26 against a forecast of -$0.22. The company saw a 44% year-over-year revenue increase, attributed to growth in Medicare Advantage and ACO Model memberships. Truist Securities maintained a Hold rating on Agilon Health, adjusting its revenue projections for fiscal years 2025 and 2026 to $5.9 billion and $6.2 billion, respectively, down from previous estimates. Additionally, Benchmark analysts raised their price target for Agilon Health shares to $4.00, highlighting the company’s alignment with fourth-quarter expectations and a conservative outlook for 2025. Stifel also increased their price target to $3.00, noting a strategic shift toward profitability over growth for 2025. Agilon Health plans to exit two unprofitable physician partnerships and anticipates a 4% decrease in Medicare Advantage membership, while expecting to gain 20,000 new members through new partnerships. The company is focused on renegotiating payer contracts and reducing Medicare Part D exposure to enhance financial stability.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.